Since March 1, new rules for regulating the pharmaceutical market that should reduce the cost of a number of medicines by almost 30%have been officially launched in Ukraine. However, in practice, this did not bring a significant relief for the wallets of Ukrainians. Manufacturers continue to control the market, and pharmacies, finding themselves in a difficult situation, are forced to look for ways to survive.
According to experts, over the past three years, medicines in Ukraine have increased by 120%, and before March "reduction" manufacturers have raised the cost of drugs by 30%in advance. The highest price was in January 2025. In spite of these facts, the President of the Association "Medicines of Ukraine" Petro Bagri denies such figures, calling them "false", although it does not provide specific counter -arguments.
Analytical data show that 71.8% of the cost of medicines is formed by manufacturers. Pharmacies affect only 22.3%and distributors by 5.9%. Ukrainian pharmacies have the lowest trading mark in Europe-14-15%. At the same time, the mark -up of manufacturers remains uncontrolled and can reach 85%.
Bagri avoids discussing these data and instead accuses the so -called "marketing contracts" of pharmacies and producers. According to new regulation, these agreements are prohibited. Manufacturers have saved about 25% of the money that went to marketing deductions, but the prices for most drugs remained high.
Reduction of prices touched only 100 drugs, selected not at the request of doctors or patients, but on the proposals of the manufacturers themselves. This list, for example, found seven species of "ascorbica" with different tastes, but not critical drugs.
At the same time, prices for other medicines that are not on the list, on the contrary - have increased. Thus, the overall effect of regulation was zero: "cheaper" returned the cost of medication only to the level of the end of 2024. For example, the drug from the pressure "Tonorm" has tripled in three years, and now just returned to the price of the early 2024.
The market is preparing for full abstracting prices, which is provided by law No. 11493, signed by the President. However, this can reduce the range, especially among international manufacturers. The European Business Association is already warning that this will have a negative impact on investors in the field of health care of Ukraine.
